VACCINE SCIENCE · MADE EXPLORABLE
Small changes.
Population-scale questions.
Plan the supply. Explore community protection. Follow the evidence behind vaccine candidates.
Educational planning tools by Prem Kumar Perumal. Illustrative scenarios, not clinical dosing guidance or outbreak forecasts.
01 / DOSES, VIALS & BUDGET
What would a programme need?
Enter your own planning assumptions. “Doses per person” means the number of administrations—not an injection volume or antigen dose.
Budget includes vaccine purchase only. Excludes staffing, transport, storage, administration and tax. No vial-sharing or session-level losses are modelled separately.
Inspect the calculation
People = round up(population × uptake). Administrations = people × doses per person. Required doses = round up[administrations ÷ (1 − wastage) × (1 + buffer)]. Round up to whole vials; budget uses every purchased dose.
A 10% wastage assumption means 90% of supplied doses are usable. It is not simply a 10% addition. Buffer is additional stock, not predicted wastage.
MSF: needs estimation ↗ · WHO wastage tools ↗02 / CHALLENGE THE ASSUMPTIONS
What changes at 90% coverage?
Compare two scenarios in the same hypothetical population. These controls are illustrative, with no particular vaccine or disease selected.
Protection here concerns infection, not protection against severe disease. These are different endpoints.
Vertical axis: currently infectious (% of total population). Horizontal axis: days. Each scenario seeds up to 0.1% of the population as infectious.
Model assumptions & limitations
Homogeneous SIR model; 365 days; fixed five-day mean infectious period; no births, deaths, waning, variants, age groups or prior immunity. Vaccination occurs before the simulation and gives complete protection to a fraction coverage × effectiveness (an all-or-nothing simplification). It is not an individual risk model.
Immune threshold = 1 − 1/R₀. Required coverage = threshold ÷ effectiveness against infection. Effective reproduction number at the start = R₀ × (1 − coverage × effectiveness). Values at exactly 1 are the theoretical boundary, not a guarantee of elimination.
Real communities have unequal contacts and coverage. This illustration cannot determine a real vaccination target. Supply and transmission panels are independent.
UK scientific advice: vaccination modelling ↗03 / EVIDENCE BEFORE EXPECTATION
Follow the candidates.
Three selected human-vaccine development examples—not a comprehensive or live pipeline. Sources checked 1 November 2026. Phase describes the cited study, not approval or a prediction of success. Open the source for subsequent changes.
How to read the pipeline
Phase 1 explores initial safety and immune response; Phase 2 expands those assessments; Phase 3 evaluates efficacy and safety in larger studies. Designs vary, and phases can overlap. A registered trial, a completed trial and regulatory approval are distinct milestones. No candidate here is ranked or recommended.
Platform descriptions and study phases are taken from the linked primary sources. Recruitment status and approval status are intentionally not inferred. This curated snapshot has no automatic update service.
Explore WHO’s vaccine pipeline resources ↗04 / ONE HEALTH · HUMAN & ANIMAL VACCINES
Shared science. Different requirements.
Both train immune responses, but a vaccine’s target species, formulation, evidence and authorised use matter. Animal vaccines are not a lower-standard version of human vaccines.
| Topic | Human vaccines | Animal vaccines |
|---|---|---|
| Who is protected? | People in defined age or risk groups; individual protection and, where supported, reduced community transmission. | Specified species, such as dogs, cattle, poultry or fish. Programmes may support animal welfare, herd or flock health and disease control. |
| One Health connection | Human health can benefit when infections are controlled at the animal–human interface. | Vaccinating relevant animal populations may reduce zoonotic risks. The impact depends on the infection and programme; it is not automatic. |
| What evidence matters? | Quality, safety and efficacy for the intended human population, assessed through laboratory work and clinical development, with continuing safety monitoring. | Quality, safety and efficacy for the target species and intended use, including duration of immunity and relevant animal, user and environmental safety considerations. |
| What counts as success? | Endpoints may include prevention of infection, clinical disease or severe outcomes. Antibody measurements alone do not always establish protection. | Endpoints depend on the claim: prevention or reduction of disease, infection, shedding or transmission. An immune response is not automatically proof of every benefit. |
| Dose and schedule | Product-specific, with age, formulation, route and schedule specified in authorised information. | Product- and species-specific, with target age, route, schedule and other conditions specified in authorised information. Animal body size alone does not determine the vaccine dose. |
| Delivery context | Individual appointments and community programmes; logistics vary with product and setting. | Companion-animal care and herd, flock or aquaculture programmes have different handling and delivery needs. Route and method must match the particular product. |
| UK product information | MHRA regulates human medicines including vaccines; use current authorised product information and clinical guidance. | VMD maintains product information for veterinary medicines authorised in Great Britain and Northern Ireland; consult the relevant product and veterinary guidance. |
Products and doses are not interchangeable. This comparison is not permission to use a human vaccine in an animal or an animal vaccine in a person. Clinical and veterinary decisions require the appropriate qualified professional.
The calculators use generic assumptions. No species-specific dose, efficacy or vaccination schedule is supplied. The candidate explorer currently contains human examples only.
